NAGE logo

Niagen Bioscience Inc

NAGE
Healthcare|Biotechnology|US
$2.07
-0.04 (-1.66%)
Tangible Book / Share
$0.98
Graham Number
$1.75

About

Niagen Bioscience, Inc. operates as a bioscience company engages in developing healthy aging products. The company operates through Consumer products; Ingredients; and Pharmaceutical Segments. It provides finished dietary supplement products that contain its proprietary ingredients directly to consumers and distributors; nicotinamide adenine dinucleotide (NAD+), an essential coenzyme that regulates cellular metabolism; and develops and commercializes proprietary-based ingredient technologies, including food-grade, Niagen, and pharmaceutical-grade Niagen and supplies these ingredients as raw materials to the manufacturers of consumer products. In addition, it commercializes NAD+ precursor nicotinamide riboside as the flagship ingredient under NIAGEN brand name. The company distributes TRU NIAGEN products direct to consumers through its propriety e-commerce platform TRUNIAGEN.com, Amazon, and other internet marketplaces, as well as specialty retailers and authorized healthcare practitioners resellers. The company was formerly known as ChromaDex Corporation and changed its name to Niagen Bioscience, Inc. in March 2025. Niagen Bioscience, Inc. was founded in 1999 and is headquartered in Los Angeles, California.

Stock Price

-68.6%(1Y)
1M
-22.2%
3M
-33.7%
6M
-50.4%
YTD
-67.5%
1Y
-70.8%
3Y
+29.4%
5Y
-67.8%

Pipeline Summary

0 total trials
0
Phase 1
0
Phase 2
0
Phase 3
0
Phase 4

Key Facts

Market Cap$163.8M
Employees117
CEORobert N. Fried
IPO DateJun 24, 2015
Beta2.09
52-Week Range$2.035 – $7.28
Avg Volume582,331
ExchangeNASDAQ

Ownership

Float65.7%
Shares Outstanding79.1M

Recent Insider Trades

Lopez Carlos LuisAWARD
Jun 30, 20262,314 shares @ $2.71
Pamir OzanAWARD
Jun 30, 20264,255 shares @ $2.71
Fried Robert NAWARD
Jun 30, 20261,106 shares @ $2.71
YU Wing Tak WendyAWARD
Jun 24, 202631,746 shares @ $3.45
Ng Wang Yu GaryAWARD
Jun 24, 202631,746 shares @ $3.45

Peers

AKBAAkebia Therapeutics, Inc.
$111.2M
CRVSCorvus Pharmaceuticals, Inc.
$886.6M
KALVKalVista Pharmaceuticals, Inc.
$1.44B
KROSKeros Therapeutics, Inc.
$185.6M
OLMAOlema Pharmaceuticals, Inc.
$641.4M
PRTAProthena Corporation plc
$409.2M
RGNXREGENXBIO Inc.
$503.0M
RIGLRigel Pharmaceuticals, Inc.
$740.7M
Data last updated: Nov 9, 2026, 04:23 AM